Clinical trials
Post-Transplant Lymphoproliferative Disorder clinical trials
Below are recruiting post-transplant lymphoproliferative disorder clinical trials, each written for real people, not researchers. We’re tracking 8 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06672705RecruitingPhase 1
Epcoritamab for post-transplant lymphoma that didn't respond to treatment
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT05786040RecruitingPhase 2
Tafasitamab plus rituximab for PTLD after solid organ transplant
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
New Brunswick, New JerseyAges 18 years+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT07368634RecruitingPhase 1/Phase 2
EBV-TCR-T cells for persistent EBV after stem cell transplant
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
BeijingAges 18–70 - NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for post-transplant lymphoproliferative disorder?
- Yes. Clin2 currently lists 8 recruiting post-transplant lymphoproliferative disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a post-transplant lymphoproliferative disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a post-transplant lymphoproliferative disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.